GE HealthCare
GEHC
$64.94
+0.09%
GE HealthCare Technologies Inc. is a leading global medical technology company operating in the healthcare information services industry, with a core business focused on imaging and ultrasound equipment, advanced visualization solutions, patient care solutions, and pharmaceutical diagnostics. The company is a market leader in medical imaging, distinguished by its strong brand, extensive installed base, and a significant recurring revenue stream from services and consumables. The current investor narrative is dominated by concerns over margin pressure and growth deceleration, as highlighted by a recent sharp stock decline following the company's reduction of 2026 earnings guidance due to significant cost inflation that its long sales cycles make difficult to offset immediately.…
GEHC
GE HealthCare
$64.94
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold. The core thesis is that GEHC is a fundamentally strong company in a tough transitional period, where the attractive valuation (11.48x forward P/E) is balanced by near-term operational headwinds, making it a 'show me' story rather than a clear buy.
Supporting evidence includes the compelling forward P/E of 11.48x, which is a significant discount to the trailing multiple and suggests deep pessimism is priced in. The company's robust $1.5B in TTM free cash flow and healthy 20.08% ROE demonstrate underlying financial strength. However, the severe -12.13% YoY revenue decline and collapsing net margin, coupled with a high PEG ratio of 4.13, justify the market's caution and the Hold rating.
This Hold would upgrade to a Buy if the company demonstrates sequential margin improvement in the next two quarters, stabilizing net income, or if the forward P/E compresses further toward 10x without a deterioration in the earnings outlook. It would downgrade to a Sell if revenue decline accelerates beyond -15% YoY or if net margin falls below 3%. Relative to its history and sector, the stock is fairly valued given the current growth and margin profile, but undervalued if a recovery materializes.
Sign up to view all
GEHC 12-Month Price Forecast
The assessment is neutral with medium confidence. The valuation is compelling, and the stock is deeply oversold, but the fundamental picture has deteriorated sharply. The key to the thesis is the trajectory of margins; evidence of stabilization would be a powerful catalyst for a re-rating. The stance would upgrade to bullish on confirmation of sequential margin improvement in the next quarterly report. It would turn bearish if the next earnings release shows further margin contraction or another guidance reduction. The high free cash flow and leading market position provide a floor, but the stock lacks a near-term growth catalyst.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $84.42 and implied upside of +30.0% versus the current price.
Average Target
$84.42
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$52 - $84
Analyst target range
The stock is covered by 9 analysts, and recent institutional ratings show a mix of Buy, Overweight, and Equal Weight/Neutral recommendations from firms like BTIG, Wells Fargo, and Morgan Stanley, indicating a generally constructive but cautious consensus view. The average estimated EPS for the covered period is $6.82, with a range from $6.71 to $6.90, and the average revenue estimate is $25.69 billion, with a range from $25.36 billion to $25.92 billion; the relatively tight range in both EPS and revenue estimates suggests analysts have a high degree of conviction in their near-term forecasts, despite the recent guidance cut. Insufficient data is available on a specific consensus price target or target range, which limits the ability to calculate a precise implied upside or downside; however, the maintained ratings by several firms following the negative news suggest some analysts see the sell-off as overdone, though the lack of a unified price target indicates ongoing uncertainty about the timing and magnitude of a recovery.
Bulls vs Bears: GEHC Investment Factors
The evidence currently leans bearish, with the severe deceleration in revenue (-12.13% YoY) and collapsing net margin (down ~960 bps) representing fundamental headwinds that outweigh the attractive valuation and strong cash flow. The most important tension in the investment debate is whether the company's significant cost inflation, which its long sales cycles make difficult to offset immediately, is a temporary operational hiccup or a symptom of a more permanent margin structure impairment. If management can demonstrate effective cost control and stabilize margins in upcoming quarters, the deeply oversold condition and low forward P/E of 11.48x could provide a powerful catalyst for a rebound. However, failure to halt the margin erosion would validate the high PEG ratio of 4.13 and likely lead to further multiple compression.
Bullish
- Strong Recurring Revenue Stream: Approximately half of GEHC's revenue is recurring from services, consumables, and digital solutions, which provides a stable base. This recurring model, estimated at one-third from servicing alone, offers resilience against cyclical equipment sales downturns.
- Attractive Forward Valuation: The stock's forward P/E of 11.48x is a significant discount to its trailing P/E of 17.97x, reflecting market pessimism priced in. This forward multiple suggests the market expects a sharp earnings recovery, making the stock appear cheap if guidance is met.
- Robust Free Cash Flow Generation: The company generated $1.506 billion in trailing twelve-month free cash flow, demonstrating strong internal funding capacity. This substantial cash flow supports operations and potential shareholder returns during a period of margin pressure.
- Deeply Oversold Technical Condition: The stock is trading only 9.6% above its 52-week low of $58.75, following a -25.70% 6-month decline. This deep oversold condition, coupled with a beta of 0.862 indicating lower volatility than the market, suggests a potential value opportunity if negative sentiment reverses.
Bearish
- Severe Growth Deceleration & Margin Pressure: Q4 2025 revenue declined -12.13% YoY, and net margin collapsed to 3.94% from 13.54% a year ago. This sharp deterioration, driven by $250M in cost inflation per recent news, is the core of the bear case and led to the 2026 guidance cut.
- High PEG Ratio Signals Overvaluation: The PEG ratio of 4.13 indicates the stock is expensive relative to its growth profile. This metric suggests the market is not pricing in sufficient future growth to justify the current earnings multiple, a major concern given the growth slowdown.
- Extreme Underperformance vs. Market: The stock's 1-year relative strength versus the S&P 500 is -39.32%, highlighting severe investor exodus. This persistent negative momentum, with a -11.57% 3-month return, reflects deep skepticism about a near-term operational turnaround.
- Analyst Uncertainty Amid Guidance Cut: While 9 analysts maintain coverage, the lack of a unified consensus price target indicates significant uncertainty following the lowered guidance. The tight EPS estimate range ($6.71-$6.90) shows conviction on numbers but not on the stock's multiple or recovery timeline.
GEHC Technical Analysis
The stock is in a pronounced downtrend, evidenced by a 1-year price change of -14.33% and a 6-month decline of -25.70%, significantly underperforming the broader market. As of the latest close of $61.59, the stock is trading at approximately 9.6% above its 52-week low of $58.75, positioning it near the bottom of its annual range, which suggests it is in a deep oversold territory that may present a value opportunity but also reflects substantial negative momentum and investor pessimism. Recent momentum remains weak, with a 3-month price change of -11.57% and a 1-month change of only +1.62%, indicating that any recent stabilization is tepid and has not reversed the longer-term bearish trend; this divergence could signal a potential bottoming process, but the stock's relative strength versus the S&P 500 is deeply negative at -39.32% over one year, underscoring severe underperformance. Key technical support is clearly defined at the 52-week low of $58.75, while resistance lies at the 52-week high of $89.77; a breakdown below support would signal a continuation of the downtrend, whereas a sustained move above the recent trading range is needed to suggest a reversal, with the stock's beta of 0.862 indicating it has been less volatile than the market during this decline, which may offer some relative downside protection.
Beta
0.86
0.86x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-10.7%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +1.2% | -2.2% |
| 3m | -6.2% | +15.8% |
| 6m | -22.3% | +6.4% |
| 1y | -10.7% | +20.9% |
| ytd | -21.6% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue growth has decelerated sharply, with the most recent quarterly revenue of $4.674 billion representing a year-over-year decline of -12.13%, a significant reversal from the prior year's growth; segment data shows the Imaging segment contributed $4.901 billion, the PCS segment $1.555 billion, and the PDx segment $1.539 billion, but the overall trend indicates broad-based pressure. Profitability has compressed considerably, with Q4 net income of $184 million and a net margin of 3.94%, down sharply from the year-ago quarter's net income of $720 million and margin of 13.54%; the quarterly gross margin of 54.30% remains robust, but operating income of $664 million and an operating margin of 14.21% reflect pressure from cost inflation and other expenses. The balance sheet shows a debt-to-equity ratio of 0.96, indicating moderate leverage, while the company generated strong trailing twelve-month free cash flow of $1.506 billion, providing solid internal funding capacity; the return on equity of 20.08% remains healthy, and the current ratio of 1.18 suggests adequate short-term liquidity to navigate the current challenges.
Quarterly Revenue
$4.7B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 17.97x, while the forward P/E is 11.48x, with the significant discount in the forward multiple reflecting market expectations for a sharp earnings recovery in the coming year. Compared to sector averages, the stock's trailing P/E of 17.97x and Price/Sales ratio of 1.82x appear reasonable; however, the PEG ratio of 4.13 suggests the stock is expensive relative to its growth profile, indicating the market is not pricing in strong future growth to justify the current earnings multiple. Historically, the current trailing P/E of 17.97x is below the stock's own historical range seen in recent quarters, which has included multiples above 50x (Q4 2025) and as low as 12.4x (Q4 2024); this positioning near the lower end of its historical band suggests the market has already priced in significant pessimism, potentially creating a value opportunity if fundamentals stabilize.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on severe profitability compression and growth deceleration. The Q4 net margin collapsed to 3.94% from 13.54% YoY, and revenue declined -12.13%, indicating fundamental pressure beyond cyclical softness. The company's moderate leverage (Debt/Equity of 0.96) is manageable, but the primary risk is that the $250M in cost inflation cited in guidance cuts becomes structural, preventing a return to historical double-digit net margins. The dependence on long sales cycles for price adjustments exacerbates this near-term margin risk.
Market & Competitive Risks include valuation compression and sector disruption. The stock's PEG ratio of 4.13 suggests it remains expensive relative to its diminished growth profile, risking further de-rating if earnings forecasts are cut again. Competitive intensity in medical imaging is high, and the recent news of RadNet's $270M AI acquisition highlights the strategic investments peers are making in automation, potentially threatening GEHC's market leadership. The stock's beta of 0.862 offers some downside protection in a market selloff, but its severe -39.32% 1-year underperformance shows it is suffering from intense company-specific selling pressure.
The Worst-Case Scenario involves a failure to contain cost inflation, leading to consecutive earnings misses and a downward revision cycle. This could trigger a loss of investor confidence in the standalone entity's growth story post-spin-off, pushing the stock toward its 52-week low of $58.75. A break below this key technical support could catalyze a washout to levels reflecting a pure value multiple, potentially around a 10x forward P/E on lowered estimates, implying a downside of approximately -20% to -25% from the current price near $61.59.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Persistent cost inflation eroding margins, as evidenced by the Q4 net margin drop to 3.94% and the $250M guidance impact. 2) Growth Risk: Continued revenue decline beyond the current -12.13% YoY, indicating market share loss or a deeper cyclical downturn. 3) Valuation Risk: Further multiple compression if the high PEG ratio of 4.13 is not justified by a growth recovery. 4) Sentiment Risk: The stock has severely underperformed the market (-39.32% 1-year relative strength), and negative momentum could persist regardless of fundamentals.
The 12-month outlook presents three scenarios. The Base Case (55% probability) sees the stock trading between $65 and $72 as the company meets lowered EPS guidance but struggles to re-accelerate growth. The Bull Case (25% probability) envisions a rally to $78-$85 on successful margin stabilization and a return to investor favor. The Bear Case (20% probability) projects a decline to retest the $58-$62 range if margins worsen further. The base case is most likely, predicated on the assumption that the severe cost pressure begins to abate but a full earnings recovery is delayed until 2027.
GEHC sends mixed valuation signals. On a forward P/E basis at 11.48x, it appears deeply undervalued relative to its own trailing multiple of 17.97x and likely the broader healthcare sector, suggesting the market has priced in significant pessimism. However, the high PEG ratio of 4.13 indicates the stock is expensive relative to its near-zero growth profile. Compared to its own historical trading range, the current P/E is near the lower end. The valuation is fair-to-cheap if earnings recover as forecasted, but it remains overvalued if the current growth deceleration and margin pressure persist.
GEHC presents a high-risk, potentially high-reward opportunity at current levels. For investors with a 2-3 year horizon and a tolerance for volatility, the stock's deep undervaluation (11.48x forward P/E) and strong cash flow ($1.5B TTM) could make it a good speculative buy. However, given the severe -12.13% revenue decline and collapsing margins, it is not a good buy for risk-averse investors or those seeking near-term growth. The investment case hinges entirely on a successful operational turnaround; therefore, it is only a good buy for those who believe management can effectively combat cost inflation and stabilize profitability.
GEHC is unsuitable for short-term trading due to its negative momentum and lack of near-term catalysts. Its beta of 0.862 suggests lower volatility than the market, but the company-specific issues dominate the price action. The stock is best suited for a long-term (3+ year) investment horizon, allowing time for management to execute its cost mitigation strategy and for the recurring revenue base to support a valuation recovery. The minimal dividend yield (0.17%) means the total return thesis relies entirely on capital appreciation from an operational turnaround. A minimum holding period of 18-24 months is suggested to assess the success of the turnaround plan.
